law://au/li/2020/f2020l01351@2026-11-13| Group T1—Miscellaneous therapeutic procedures | ||
|---|---|---|
| Subgroup 13 – Miscellaneous therapeutic procedures | ||
| Column 1Item | Column 2Description | Column 3Fee ($) |
| 14247 | Extracorporeal photopheresis for the treatment of erythrodermic stage III-IVa T4 M0 cutaneous T-cell lymphoma; if(a) the service is provided in the initial six months of treatment; and(b) the service is delivered using an integrated, closed extracorporeal photopheresis system; and(c) the patient is 18 years old or over; and(d) the patient has received prior systemic treatment for this condition and experienced either disease progression or unacceptable toxicity while on this treatment; and(e) the service is provided in combination with the use of Pharmaceutical Benefits Scheme-subsidised methoxsalen; and(f) the service is supervised by a specialist or consultant physician in the speciality of haematology.Applicable once per treatment cycle (H) | 1,925.55 |
| 14249 | Extracorporeal photopheresis for the continuing treatment of erythrodermic stage III-IVa T4 M0 cutaneous T-cell lymphoma; if(a) in the preceding 6 months:(i) a service to which item 14247 applies has been provided; and(ii) the patient has demonstrated a response to this service; and(iii) the patient requires further treatment; and(b) the service is delivered using an integrated, closed extracorporeal photopheresis system; and(c) the patient is 18 years old or over; and(d) the service is provided in combination with the use of Pharmaceutical Benefits Scheme-subsidised methoxsalen; and(e) the service is supervised by a specialist or consultant physician in the speciality of haematology.Applicable once per treatment cycle (H) | 1,925.55 |
Sourced from the Federal Register of Legislation at legislation.gov.au, © Commonwealth of Australia, licensed under CC BY 4.0. Compilations may have been reformatted.